SuperworthBiofrontera BFRI
- Market cap
- $11.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $46.2M
- +18% on a year ago
- Net margin
- −13.8%
- Free cash flow yield
- −67.7%
Biofrontera trades at 0.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $46.2M over the last twelve months, up 18% on a year earlier with a −14% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8.9M+106% | $10.6M+5% | $7.9M−9% | $7.8M+34% | $9M+1% | $12.6M+19% | $8.6M+9% | $9M+15% | $7M−23% | $17.1M+36% | $10.1M+17% | $12M+33% | |
| Cost of revenue | $4.6M+106% | $5.4M+2% | $4.1M−11% | $4.3M+50% | $4.9M+6% | $5.3M−2% | $3.3M−21% | $2.6M−39% | $2M−58% | $3M−43% | $2.1M−35% | $2.4M−9% |
| Gross profit | $4.3M+105% | $5.2M+7% | $3.8M−8% | $3.5M+18% | $4.1M−4% | $7.3M+39% | $5.3M+40% | $6.4M+83% | $4.9M+20% | $14.1M+93% | $8M+50% | $9.6M+50% |
| R&D | $33K | $33K | $17K | $621K+5546% | $669K+1927% | $783K+2273% | $1.2M+7000% | $870K+40% | $854K+28% | $787K+1% | $900K−25% | $448K−49% |
| SG&A | $8.7M+12% | $9.1M−10% | $9.3M+34159% | $7.9M+8503% | $8.4M−3% | $8.2M−10% | $8.7M−7% | $10.5M+33% | $10M+19% | $8.5M+4% | $11M+27% | $9.6M−9% |
| −$4.6M+27% | −$3.9M−31% | −$5.5M−1% | −$5.1M−42% | −$5M+7% | −$1.7M−56% | −$4.5M−17% | −$5.1M+0% | −$6.3M+27% | $4.6M | −$4.3M−5% | −$524K−90% | |
| Interest expense | $142K+60% | −$36K | $1.4M+70950% | $596K+1763% | n/a | n/a | $106K−93% | $115K−81% | n/a | n/a | $125K+18% | $126K+10% |
| Pre-tax income | −$6.3M+147% | $3.5M | −$10.4M+40% | −$237K−98% | −$5.7M−11% | −$1.4M | −$4.2M−60% | −$5.3M+2138% | −$6.6M+17% | $5.6M | −$4.8M+13% | −$581K−89% |
| $1K+0% | −$6K | $1K−80% | $20K+43% | $3K+200% | −$3K−50% | −$1K | $21K+5% | $6K+100% | $0 | n/a | $23K+10% | |
| Net income | −$6.3M+147% | $3.5M | −$10.4M+40% | −$257K−97% | −$5.7M−11% | −$1.4M | −$4.2M−60% | −$5.3M+1972% | −$6.6M+17% | $5.6M | −$4.8M+13% | −$604K−89% |
| −$4.64+105% | $1.65 | −$2.88−49% | −$0.05−99% | −$0.98−79% | −$0.18 | −$0.47−84% | −$0.57+1040% | −$0.62−37% | $0.48 | −$0.41−13% | −$0.05−91% | |
| 1.4M+20% | 2.1M+66% | 3.6M+171% | 5.1M+274% | 5.8M+322% | 7.6M+253% | 8.9M+145% | 9.4M+84% | 10.8M+87% | 11.6M+54% | 11.7M+32% | 12.9M+38% |
Gross profit: 24 periods, Q3 FY20 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY21 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Biofrontera's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BFRIBiofrontera | $11.7M | n/m | n/a | 0.3× | +18% | −13.8% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Biofrontera
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .